Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 18, 2026 (U.S. Pacific time), EBR Systems, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually via live webcast. At the Special Meeting, the Company’s stockholders voted on the three proposals set forth below.…
Filed Aug 20, 2026Accepted Aug 20, 2026, 3:00 PM EDTCIK 1347123Accession 0001214659-26-010643
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 18, 2026 (U.S. Pacific
time), EBR Systems, Inc. (the “ Company ”) held a Special Meeting of
Stockholders (the “Special Meeting”) virtually via live webcast. At the Special Meeting, the Company’s
stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s
Proxy Statement filed with the Securities and Exchange Commission on July 9, 2026 (the “Proxy Statement”).
Proposal 1 - Ratification of Security Issuances. The Company’s stockholders approved the ratification of the issuance of 77,352,890 CDIs
(equivalent to 7,735,289 shares of common stock) at an issue price of A$0.38 per CDI, on terms and conditions set out in the Proxy Statement,
pursuant to and for the purposes of Australian Securities Exchange (“ASX”) Listing Rule 7.4. The results of the vote were:
For Against Abstain Broker Non-Vote Uncast *
─────────────────────────────────────────────────────────────────────────────
34,724,458 485,633 1,750,135 0 0
* Represents shares underlying votes that were
not cast held by holders subject to a voting exclusion on the matter or that were disregarded, pursuant to ASX Listing Rule 14.11.1, as
further described in the Proxy Statement
Proposal 2 - Approval of Security Issuances. The Company’s stockholders approved the issuance of 92,105,270 CDIs (equivalent to 9,210,527
shares of common stock) at an issue price of A$0.38 per CDI to certain clients of BCP3 Pty Ltd, an associate of Dr. Chris Nave (a non-executive
director of the Company), on terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule
10.11. The results of the vote were:
For Against Abstain Broker Non-Vote Uncast *
───────────────────────────────────────────────────────────────────────────────
24,746,794 512,726 1,119,243 0 10,581,462
Proposal 3 - Adjournment of Special Meeting. The Company’s stockholders approved the adjournment of the Special Meeting, if necessary,
to solicit additional proxies if there are not sufficient votes in favor of the Proposal 1 or Proposal 2. The results of the vote were:
For Against Abstain Broker Non-Vote Uncast
─────────────────────────────────────────────────────────────────────────
36,960,227 0 0 0 0
No other matters were submitted for stockholder
action at the Special Meeting.